×
Dave Picard

Dave Picard

Chief Commercial Officer

Dave is a senior executive with an established track record of successfully leading sales teams and growing businesses. Most recently, he served as SVP, Global Generic Pharmaceuticals for AmerisourceBergen where he was responsible for elevating ABC’s presence in the generic injectable space. Previously with Sandoz for 13 years, Mr. Picard was the Vice President, Institutional Sales and Marketing.

Dave holds a Master of Business Administration degree from the Robert Morris University.

Copyright ©2021 all rights reserved

Hydroxyprogesterone

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena® (hydroxyprogesterone caproate injection, 250 milligrams (mg) per mL) and its generics. FDA recognizes that there is a supply of product that has already been distributed. Patients who have questions should talk to their healthcare provider. We recommend health care practitioners consider FDA’s conclusions.

If you have questions or concerns about receiving your therapy as prescribed, consult your healthcare provider.

https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena